{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:25:48Z","timestamp":1792113948947,"version":"4.4.0"},"reference-count":49,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Molecular treatments for Duchenne muscular dystrophy (DMD) are already in clinical practice. One particular means is exon skipping, an approach which has more than 15 years of background. There are several promising clinical trials based on earlier works. The aim is to be able to initiate the production of enough dystrophin to change the rate of progression and create a clinical shift towards the better. Some of these molecules already have received at least conditional approval by health authorities; however, we still need new accumulating data.<\/jats:p>","DOI":"10.3390\/genes13071241","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:17:10Z","timestamp":1657844230000},"page":"1241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-4162","authenticated-orcid":false,"given":"G\u00f6k\u00e7e","family":"Eser","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Yeditepe University School of Medicine, \u0130stanbul 34755, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3545-3830","authenticated-orcid":false,"given":"Haluk","family":"Topalo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yeditepe University School of Medicine, \u0130stanbul 34755, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","unstructured":"Duchenne, G.B. (2022, February 23). Selections from the Clinical Works of Dr. Duchenne (de Boulogne), Available online: http:\/\/archive.org\/details\/selectionsfromc00poorgoog."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(00)04052-6","article-title":"The dystrophy of Duchenne","volume":"357","author":"Jay","year":"2001","journal-title":"Lancet Lond. Engl."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gao, Q.Q., and McNally, E.M. (2015). The Dystrophin Complex: Structure, Function, and Implications for Therapy. Comprehensive Physiology, John Wiley & Sons, Ltd.","DOI":"10.1002\/cphy.c140048"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"ref_6","unstructured":"Swaiman, K.F., Ashwal, S., Ferriero, D.M., Schor, N.F., Finkel, R.S., Gropman, A.L., Pearl, P.L., and Shevell, M.I. (2017). 135\u2014Muscle and Nerve Development in Health and Disease. Swaiman\u2019s Pediatric Neurology, Elsevier. [6th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-Skipping in Duchenne Muscular Dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: The physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Beekman, C., Janson, A.A., Baghat, A., van Deutekom, J.C., and Datson, N.A. (2018). Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195850"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1750-3639.1996.tb00780.x","article-title":"Dystrophin and its isoforms","volume":"6","author":"Kunkel","year":"1996","journal-title":"Brain Pathol. Zur. Switz."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Fokkema","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy","volume":"53","author":"Ginjaar","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nmd.2014.09.004","article-title":"204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24\u201326 January 2014, Naarden, The Netherlands","volume":"25","author":"Ferlini","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1073\/pnas.88.8.3243","article-title":"Tissue distribution of the dystrophin-related gene product and expression in the mdx and dy mouse","volume":"88","author":"Love","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: One gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0960-8966(99)00048-6","article-title":"Expression, regulation and localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle","volume":"9","author":"Torelli","year":"1999","journal-title":"Neuromuscul. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.nmd.2012.05.016","article-title":"The inside and out of dystroglycan post-translational modification","volume":"22","author":"Moore","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2001-2-4-reviews3006","article-title":"Dystrophins and dystrobrevins","volume":"2","author":"Roberts","year":"2001","journal-title":"Genome Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41431-020-0643-7","article-title":"EMQN best practice guidelines for genetic testing in dystrophinopathies","volume":"28","author":"Fratter","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00283688","article-title":"Molecular deletion patterns in Duchenne and Becker type muscular dystrophy","volume":"81","author":"Koenig","year":"1989","journal-title":"Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: Analysis of More than 7000 Duchenne Muscular Dystrophy Mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrg3460","article-title":"Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches","volume":"14","author":"Fairclough","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-61779-767-5_23","article-title":"Overview of alternative oligonucleotide chemistries for exon skipping","volume":"867","author":"Saleh","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., and Falzarano, M.S. (2017). Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules, 22.","DOI":"10.3390\/molecules22040563"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense Oligonucleotide Therapies for Neurodegenerative Diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Fokkema","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-Human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"ref_38","unstructured":"(2022, June 08). Golodirsen: First Approval\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/32026421\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Clemens, P.R., Rao, V.K., Connolly, A.M., Harper, A.D., Mah, J.K., McDonald, C.M., Smith, E.C., Zaidman, C.M., Nakagawa, T., and Hoffman, E.P. (2022). Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. J. Neuromuscul. Dis., preprint.","DOI":"10.3233\/JND-220811"},{"key":"ref_43","unstructured":"(2022, June 08). Sarepta Therapeutics Announces FDA Approval of AMONDYS 45TM (Casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45. Available online: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-approval-amondys-45tm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: A first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/mt.2013.121","article-title":"AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy","volume":"21","author":"Goyenvalle","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"ref_48","unstructured":"Dearment, A. (2022, July 05). Astellas\u2019 Audentes Therapeutics Discloses Third Patient Death in Gene Therapy Trial. MedCity News. Available online: https:\/\/medcitynews.com\/2020\/08\/astellas-audentes-therapeutics-discloses-third-patient-death-in-gene-therapy-trial\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.3233\/JND-210706","article-title":"The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response after AAV Gene Therapy in Dystrophin Deficient mdx Mice","volume":"8","author":"Li","year":"2021","journal-title":"J. Neuromuscul. Dis."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/7\/1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:50:05Z","timestamp":1760140205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/7\/1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["genes13071241"],"URL":"https:\/\/doi.org\/10.3390\/genes13071241","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}